Sibgat A. Choudhury PhD
Keynote Speaker
Director, R&D
Metamark Genetics Inc.
Dr. Choudhury is working as Director, Research and Development at Metamark Genetics Inc., a Biotechnology company involved in the diagnosis and management of prostate and bladder cancer along with other urologic conditions. Prior to this appointment he worked as a Senior Scientist and Scientist in the same company. He was instrumental in developing the first protein based prognostic test for prostate cancer using quantitative multiplex immunofluorescence (QMIF) platform. The test that differentiates aggressive from non-aggressive cases is currently available for prostate cancer patients in USA.
Dr. Choudhury did his undergraduate and graduate studies in Biochemistry and Molecular Biology at the University of Dhaka, Bangladesh. He studied Molecular Biology at Long Island University, NY and later completed his PhD from prestigious McGill University, Canada. He worked on DNA damage repair mechanisms during his PhD studies at McGill under Dr. Terry Chow, who did pioneering work on DNA repair mechanisms using yeast as a model system.
After completing his PhD, Dr. Choudhury moved to Dana Farber Cancer Institute, Harvard Medical School as a Research Fellow, where he worked at a world-renowned Breast Cancer laboratory with Professor Kornelia Polyak. His ground-breaking research at DFCI/Harvard medical school deciphered how early full-term pregnancy confers resistance to breast cancer. Dr. Choudhury published many articles in international peer-reviewed journals and his research works were also mentioned in Scientific Newspapers and Bulletin with a headline. He has a patent on “Methods for treating, preventing and predicting risk of developing breast cancer.”
Current Position:
Director, R&D
Metamark Genetics Inc.
Contact
Email: youremailaddress